Clinical Trial

Treatment of Advanced Cancers

Study Description

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Ciforadenant

100 mg orally twice daily for the first 14 days of each 28-day cycle.

Drug - Ciforadenant

100 mg orally twice daily for 28 days of each 28-day cycle.

Drug - Ciforadenant

200 mg orally once daily for the first 14 days of each 28-day cycle.

Drug - Ciforadenant + atezolizumab

Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.

Drug - Ciforadenant

Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.

Additional Information

Official Study Title

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Clinical Trial ID

NCT02655822

ParticipAid ID

1aMW1d